A powerful whole
organism model for accelerating ageing research
Measuring decline in neuronal function with age
C. elegans, with its well-mapped nervous system and neurotransmitter similarities to humans, presents a unique model for studying age-related cognitive decline. The decline in dopaminergic responses associated with ageing mirrors conditions like Parkinson’s disease (PD) in humans.
Current behavioural assays using rodents for studying cognitive decline are expensive, time-consuming, and lack translatability to human conditions, hindering progress in anti-ageing therapeutic development.
Magnitude Biosciences leverages C. elegans and our proprietary WormGazerTM technology to provide our novel Age-related Cognitive (ARC) Functional Assay. This assay quantifies cognitive decline in aged worms and neurodegenerative disease models, offering a cost-effective and efficient alternative to rodent models.
Our ARC assay measures cognitive function through a chemotaxis-dependent behavior that declines with age. By automating data acquisition with our WormGazerTM technology, we can evaluate the effects of compounds on cognitive health in C. elegans.
Control
Normal mobility & exploration
Can recognises food source & stay near it
Disease A
Normal mobility & exploration
Impaired cognitive function results in failure to recognise and move towards food
Disease B
Impaired mobility & exploration
Can recognise food source & stay near it
Worms of various ages are placed a fixed distance from their food source. As they age, it takes longer for them to find their food, and they are less able to cognitively localise themselves to the food.
Collaborate with Magnitude Biosciences to accelerate your research on age-related cognitive decline. Our ARC assay provides a streamlined approach to assess compound efficacy.
Contact us today to explore how our ARC assay can advance your research on age-related cognitive decline and support the development of anti-ageing therapeutics.
SERVICES
Contract lab services for your research area
Sign up to our newsletter today, to get access to the latest company and industry news